1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69103806B0266C972002585DF004852A2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-analytics-insights-teams-across-biopharma-organization-innovation-coe-patient-engagement-covid-19-support?opendocument
18
19opendocument
203.237.186.116
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Innovation Centers of Excellence, Patient Engagement and COVID-19 Support

ID: 5643


Features:

10 Info Graphics

13 Data Graphics

100+ Metrics

8 Narratives


Pages/Slides: 31


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Innovation Centers of Excellence, Patient Engagement and COVID-19 Support”

STUDY OVERVIEW

In an increasingly complex and ever-changing biopharma marketplace, organizations that leverage their Analytics and Insights (A&I) teams for advanced data-driven decision making will have an advantage over their peers.

Consequently, forward-looking companies are streamlining the operations of their Analytics and Insights function to drive new improvements and scale innovation.

Best Practices, LLC conducted this benchmarking research to help the Analytics & Insights (A&I) group within biopharma companies make decisions to maximize its impact and leverage its analytics capabilities to provide effective strategic consultation, grow service demand, promote innovation and scale successes.

The study also examines the role played by A&I teams in supporting Innovation Centers of Excellence and patient engagement, and the new opportunities and challenges that have emerged for A&I groups as a result of COVID-19.

KEY TOPICS

  • Innovation centers of excellence: Usage, staffing, services and alignment
  • Innovative pilots, design thinking and patient engagement
  • A&I support during COVID-19 and beyond

KEY METRICS
  • Does your company have an Innovation Center of Excellence (CoE) to leverage expertise and drive new improvements?
  • What is the relationship between your Innovation CoE (or similar department) and your Analytics & Insights group?
  • How many FTEs work in your Innovation CoE (or similar department)?
  • How effective are each of the listed services delivered by your Innovation CoE (or similar group) in supporting the overall organization?
  • What professional experiences are critical for success for staff working in an Innovation CoE or similar department?
  • Do any groups in your organization employ a formal Design Thinking methodology to achieve better performance over time?
  • Does your organization engage directly with patients to better understand and meet their lifestyle needs relative to the disease state treated by your company’s medicines?
  • In what areas has your organization made a positive impact using patient engagement programs to better meet patient needs?

SAMPLE KEY FINDINGS
  • Effective Services:
    • Ad hoc consultation, centralizing resources and conducting seminars are among most effective services.
    • Some find it highly effective to embed CoE staff within brands or other critical units.
METHODOLOGY

Best Practices, LLC engaged 44 Analytics and Insights professionals from 38 leading biopharma organizations in this research through a benchmark survey. Data in this study are segmented by mid vs. large pharma companies. Deep-dive interviews were conducted with selected benchmark participants to provide further insights. Over 85% of research participants serve at the director level or above.


Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Research; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Alkermes; Amgen; Arena Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; Bayer; Bio-Rad Laboratories; Inc.; Biotest AG; Biotronik; Boehringer Ingelheim; B.Braun; Dermira; Edwards Lifesciences; GlaxoSmithKline ; Grünenthal; Janssen; Klosterfrau Healthcare Group; LEO Pharma; Lonza Inc.; MEDiSTRAVA; Merck; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Momenta; Novartis; Pfizer; Qiagen; REGENXBIO Inc.; Sanofi; Santen; Scilex Pharmaceuticals; Seqirus; Servier; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.